Arcticzymes Technologies ASA represents values of innovation, collaboration, and sustainability. As a company, Arcticzymes is dedicated to providing high-quality products and services to the life sciences industry. They strive to continuously develop and improve their enzyme technologies, offering innovative solutions for research, diagnostics, and therapeutics. Arcticzymes values collaboration, actively working with partners and customers to meet diverse scientific needs. Furthermore, the company is committed to sustainability by implementing environmentally friendly processes and promoting responsible business practices. Arcticzymes Technologies ASA embodies a corporate philosophy centered around excellence, integrity, and contributing to advancements in the life sciences field.

Arcticzymes Technologies ASA is primarily present in a number of countries and regions worldwide. The company has a global presence, with a strong focus on Europe, specifically within the Nordic region. Additionally, Arcticzymes Technologies ASA has established a significant presence in North America, specifically in the United States and Canada. The company's broad geographic reach allows it to cater to a wide range of international customers and partnerships.

Arcticzymes Technologies ASA has achieved several significant milestones. The company has developed a reputation as a leader in the field of molecular biology enzymes and technologies. Among their notable achievements is the successful development and commercialization of innovative enzymes used in various applications, such as PCR and DNA sequencing. They have also established strong partnerships with renowned research institutions, leading to the creation of cutting-edge products. Arcticzymes Technologies ASA has continuously invested in research and development to enhance their product portfolio and expand their market presence. Their commitment to scientific excellence and customer satisfaction has propelled them to become a trusted name in the industry.

Arcticzymes Technologies ASA is a Norwegian biotechnology company specializing in the development and production of novel enzymes for molecular biology applications. Founded in 2002, Arcticzymes has a rich history of providing innovative solutions to the life science industry. With a focus on marine enzymes, the company has developed a diverse portfolio of products that find applications in research, diagnostics, and therapeutics. Arcticzymes is committed to sustainability and sources its enzymes from diverse Arctic marine organisms, ensuring minimal impact on the environment. The company's dedication to quality, innovation, and environmental responsibility has made Arcticzymes Technologies ASA a trusted partner in the global biotech community.

Arcticzymes Technologies ASA faces competition from several companies in the market. Some of its main competitors include Company A, Company B, and Company C. These competitors offer similar products and services, presenting options for customers seeking alternatives to Arcticzymes Technologies ASA. However, Arcticzymes Technologies ASA maintains its unique value proposition through its innovative technologies and unparalleled expertise, ensuring its position as a leading player in the market.

Arcticzymes Technologies ASA primarily operates within the biotechnology industry.

The business model of Arcticzymes Technologies ASA revolves around the development and production of high-quality enzymes for use in molecular research, diagnostics, and therapeutics. With a focus on the cold-adapted enzyme market, Arcticzymes utilizes its expertise to provide biotechnology companies and research institutions with innovative enzymes. By leveraging its unique access to Arctic marine resources, the company is able to produce enzymes with exceptional properties, such as increased stability and activity at low temperatures. Arcticzymes' business model aims to cater to the growing demand for specialized enzymes in various industries, offering effective solutions for customers globally.

De Arcticzymes Technologies A K/W is 44,13.

De Arcticzymes Technologies A KUV is 8,21.

De AlleAktien Kwaliteitsscore voor Arcticzymes Technologies A is 3/10.

De verwachte Arcticzymes Technologies A omzet is 130,29 mln. NOK.

De verwachte Arcticzymes Technologies A winst is 24,24 mln. NOK.

Arcticzymes Technologies ASA is a Norwegian biotechnology company specializing in the production of enzymes for use in molecular biology, diagnostics, and therapeutics. The company was founded in 2002 and is headquartered in Tromsø, Norway. It is divided into three business areas: enzymes, reagents, and custom solutions. The enzyme business is the core business of Arcticzymes Technologies ASA, offering a wide range of enzymes for various applications. The reagents category includes various reagents for molecular biology, including buffers, gels, and dyes for gel electrophoresis, as well as RT-qPCR reagents for real-time polymerase chain reaction. The company also offers custom solutions for customers, developing tailored enzymes or reagents for specific applications. Arcticzymes Technologies ASA emphasizes continuous innovation, investing in research and development to develop new enzymes and reagents. It also collaborates with other companies and research institutes to advance its R&D efforts and develop new products. Overall, Arcticzymes Technologies ASA focuses on producing enzymes and reagents for molecular biology and diagnostics, offering high-quality products and actively investing in R&D.

Arcticzymes Technologies A keert een dividend van 0 NOK uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Arcticzymes Technologies A of het bedrijf keert geen dividend uit.

De ISIN van Arcticzymes Technologies A is NO0010014632.

Het WKN van Arcticzymes Technologies A is A0HGR5.

De ticker van Arcticzymes Technologies A is AZT.OL.

Binnen de laatste 12 maanden betaalde Arcticzymes Technologies A een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Arcticzymes Technologies A naar verwachting een dividend van 0 NOK betalen.

De dividendrendement van Arcticzymes Technologies A is momenteel .

Arcticzymes Technologies A betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Arcticzymes Technologies A betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 NOK verwacht. Dit komt overeen met een dividendrendement van 0 %.

Arcticzymes Technologies A wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Arcticzymes Technologies A van 27-8-2024 ter hoogte van 0 NOK te ontvangen, moest je het aandeel voor de ex-datum op 27-8-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 27-8-2024.

In het jaar 2023 heeft Arcticzymes Technologies A 0 NOK aan dividenden uitgekeerd.

De dividenden van Arcticzymes Technologies A worden in NOK uitgekeerd.